HPV cervical cancer screening: cobas® HPV test

This App is for secondary and primary care clinicians involved in cervical screening and the prevention of cervical cancer. It comprehensively covers key information on Human Papillomavirus (HPV) and HPV testing in cervical cancer screening and the Roche cobas® HPV Test.

What is covered in this app?
•The facts on HPV
•Cytology and HPV
•HPV testing
•Integration of HPV testing as Triage and Test of Cure in cervical screening
•How genotyping can help you in patient management
•The future of cervical screening
•‘Patient consultation’ films allow you to explore discussion of an HPV test result.
•Information on the Roche cobas® HPV Test, a test frequently used in cervical screening and how the test works can be discovered.
•The ATHENA (Addressing THE Need for Advanced HPV diagnostics) trial: a large landmark US-based, multisite, regulatory trial designed with three specific objectives: to clinically validate the performance of the cobas HPV Test as a triage test for women with abnormal squamous cells of undetermined significance (ASCUS)/borderline cytology; to validate the test as an adjunct test to guide clinical management in women aged 30 years and older with negative cytology results (NILM) and to evaluate the performance of test as a first-line test in women ≥25 years. ATHENA is the first US trial evaluating high-risk HPV DNA testing as a stand-alone cervical screening test.

Roche, makers of the cobas® HPV test, is a leader in research based healthcare with combined strengths in pharmaceuticals and diagnostics and is also the world leader in in-vitro diagnostics and diabetes management. Roche aims at providing medicines and tools that enable people live in better health for longer.

Created by Roche Diagnostics Limited. All rights reserved.